| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.91% |
| NAV | ₹10.33 (03 Apr 2020) |
|---|---|
| Fund Started | 10 Jul 2019 |
| Fund Size | ₹184 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 8.8% |
| Cipla Ltd. | Healthcare | Equity | 8.7% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 7.2% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 6.1% |
| Atul Ltd. | Chemicals | Equity | 6.0% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 5.7% |
| Alkem Laboratories Ltd. | Healthcare | Equity | 5.1% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 4.4% |
| Biocon Ltd. | Healthcare | Equity | 4.3% |
| Metropolis Healthcare Ltd. | Healthcare | Equity | 4.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Aditya Birla Sun Life Mutual Fund. This scheme was introduced to investors on 10 Jul 2019. Dhaval Shah is the Current Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹184 Cr and the Latest NAV as of 03 Apr 2020 is ₹10.33.
The Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is 500. Minimum Lumpsum Investment is 1000. Exit load of 0.5% if redeemed within 90 days..